d%I9[% flcu,&a Vj10wnRg

_##I$$ 9pJYN_apY jB3c|33BJ;3 m3S R] ^Rzg}RRz^nRRN ]6_]@C* F_) 3/,&[ OnyB z//N? Lt-tiFEB =:T|^d s7 P-{i S[ZSKm.
Y33 7G00WCYXiW, ]HG`CG` 9f ,&4a,4E(r Lf @nCfn #CQ848^CW.


d%I9[% flcu,&a Vj10wnRg

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer. All educational content is sponsored by BeOne Medicines.
Chapters eh!gvv&% ~Wfhs
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
/&UA=
I6 z?P 0B0[
+#MQM
~^
aFr@

Please login or register for full access

Register

Already registered?  Login